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CORRESPONDENCE
Letters to the Editor
Assessing Risk After
Acute Myocardial Infarction
Mahmarian et al. (1) recently published the INSPIRE (AdenosINe
Sestamibi SPECT Post-InfaRction Evaluation) trial, a prospective
study comparing intensive medical therapy to revascularization in
stable patients following ST-segment elevation myocardial infarc-
tion (STEMI) or non-STEMI with demonstrable ischemic bur-
den on myocardial perfusion imaging (MPI). Medical therapy was
shown to be equivalent to revascularization, decreasing the ische-
mic burden at 2 months assessed by repeat MPI. The 1-year
clinical outcomes were also assessed, but the study was not
powered to detect any differences, and, predictably, did not.
Thus, medical therapy in stable patients with reversible perfu-
sion defects following an MI provided a short-term reduction in
ischemic burden comparable to that of revascularization. However,
although medical therapy may be comparable to revascularization
for improving inducible ischemia—or, as pointed out in the
accompanying editorial (2), “the heterogeneity of myocardial blood
flow induced by adenosine”—this does not mean that the strategies
are clinically equivalent. Inducible ischemia and clinical outcomes
do not necessarily go hand-in-hand.
The MPI was used to demonstrate “high-risk” anatomy; how-
ever, the trial excluded patients at high clinical risk who might
have benefited more from revascularization or patients who un-
derwent primary or early percutaneous revascularization for their
index event (a strategy many consider to be the treatment of
choice). Despite a “high-risk” perfusion study (performed an
average of 12 days after admission), patients in this study had
already declared themselves as being at relatively low clinical risk.
Furthermore, maximal medical therapy (excluding anti-
anginals) remains the standard of care for all patients with coronary
disease. In this trial, the treatment arms were not matched
regarding intensity of medical treatment. Patients in the medical-
therapy arm were more likely to be on dual-antiplatelet therapy
(aspirin/clopidogrel), lipid-lowering agents, and angiotensin-
converting enzyme (ACE) inhibitors. Patients who underwent
revascularization had the additional variable of less intensive
medical treatment. Few, if any, interventional cardiologists would
argue against the importance of intensive medical therapy post-
revascularization.
What we have learned from Mahmarian et al. (1) is that
intensive medical therapy has a greater impact on adenosine-
induced ischemia than previously appreciated. However, important
questions remain. The heterogeneous nature of the population is
never fully accounted for, but there may be real differences between
STEMI and NSTEMI patients. Additionally, 26 patients in the
medical therapy group were revascularized, and 24 patients in the
revascularization group were not; the reasons for this “crossover”
are not explained, and therefore the intention-to-treat analysis is
flawed.
The benefit of intensive medical therapy in patients following
an MI remains indisputable. However, a policy shift away from
early revascularization strategies in favor of MPI following an MI
is not supported by the INSPIRE study. Before utilizing MPI,
hard evidence supporting actual clinical benefit is needed.
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Reply
We appreciate the opportunity to re-emphasize the clinical mes-
sages from the (INSPIRE) trial (1,2). Patients at very high clinical
risk and those who had percutaneous coronary intervention (PCI)
for acute ST-segment elevation myocardial infarction (MI) were
excluded from INSPIRE because PCI is the preferred approach in
these settings. The INSPIRE cohort still represents 75% of
acute myocardial infarction (AMI) patients today who do not
receive acute PCI but who still are at substantial risk for subse-
quent events. In fact, 64% of our low Thrombolysis In Myocardial
Infarction (TIMI) risk-score patients had intermediate- or high-
risk scintigraphic characteristics resulting in a high 1-year event
rate of 15%.
The purpose of imaging is not only to stratify risk but also to
determine in whom risk can be reduced. The low- and
intermediate-risk groups in INSPIRE (which represented two-
thirds of all enrolled patients) would have unlikely benefited from
coronary revascularization owing to their low initial risk or lack of
inducible ischemia, respectively. The INSPIRE results comple-
ment the findings from the OAT (Occluded Artery Trial) (3),
which showed no advantage (and potential harm) from PCI and
stenting of occluded arteries post-AMI in patients who lacked
significant ischemia. Adenosine single-photon emission computed
tomography (SPECT) is a practical initial imaging method to
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identify such patients and thereby avoid unnecessary and costly
invasive procedures.
With regard to the randomized cohort, the comparable reduc-
tion in scintigraphic ischemia among the 2 strategies led to similar
1-year event rates. The crossover rates are similar to those reported
in other acute coronary syndrome trials and were comparable
between the two strategies. Although INSPIRE was underpow-
ered to categorically assess differences in event rates between
strategies, it provides event rate estimates for designing an ade-
quately powered outcome trial. The main INSPIRE trial results
give strong support for the premise that the presence and extent of
scintigraphic ischemia predict risk and are surrogate markers for
cardiac events.
Medical therapy is appropriate in all post-AMI patients, but it
is usually not maximized. In INSPIRE, most patients in both
randomized strategies received antiplatelet agents, beta-blockers,
and statins. However, INSPIRE was unique in mandating maxi-
mally tolerated doses of all classes of anti-ischemic medications to
patients in the medical-therapy limb. The objective was to mini-
mize scintigraphic ischemia—a goal achieved in the majority of
patients.
Both INSPIRE (1,2) and other recently published trials (3,4)
provide new evidence that a conservative approach of early risk
stratification through noninvasive imaging is not only reasonable
but appropriate in the majority of patients post-AMI so as to
identify those most likely to benefit from coronary revasculariza-
tion. Finally, INSPIRE also shows that in patients with ischemia
and preserved left ventricular function, intensive medical therapy is
an excellent initial treatment option.
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Hyperthyroidism and Mortality
Hyperthyroidism is associated with systemic inflammation (1)
atrial fibrillation (2), and vascular and left ventricular hypertrophy
(3,4). It is therefore reasonable to assume an increased mortality in
patients with overt hyperthyroidism compared to euthyroid sub-
jects. The effects of hyperthyroidism on all-cause and circulatory
mortality, however, are a matter of debate and subject to ongoing
controversy. Some investigations demonstrated increased mor-
tality in hyperthyroid compared to euthyroid subjects (5,6), but
others did not confirm this finding (7–9). One study even
revealed lower mortality in hyperthyroid compared to euthyroid
elderly subjects (10).
In a previous issue of JACC, Osman et al. (11) analyzed
mortality of 393 patients with overt hyperthyroidism and 393 age-
and gender-matched euthyroid subjects. During the 66.6 months
of follow-up, 26 patients died, 7 of them from circulatory causes,
whereas 12 euthyroid subjects died, 4 of them from circulatory
causes. Unfortunately, risk estimates, including levels of statistical
significance, were not given.
As correctly stated by Osman et al. (1), interpretation of their
results is hampered by the low number of deceased subjects.
Further limitations, however, should be considered and discussed.
First, a number of potential factors confound the association
between hyperthyroidism and mortality. Osman et al. (11) con-
trolled for gender and age by study design. In addition, imbalances
between hyperthyroid and euthyroid subjects with regard to
current smoking (29% vs. 15%, p  0.0001) and diabetes mellitus
(6% vs. 3%, p  0.1) will have strong effects on the group-specific
mortality risk in their study. Thus, analyses should also be
controlled for at least these 2 factors.
Second, the outcome in patients who undergo a specific treat-
ment depends upon various characteristics, including risk factors
for the disease, the disease itself, comorbidities influencing the
choice of a specific therapy, and desired and undesired treatment
effects. Increased mortality in patients with hyperthyroidism seen
in the study by Osman et al. (11) might therefore be explained at
least hypothetically by, for example, the type of and the indication
for a specific antithyroid therapy and the status of thyroid function
following treatment.
Third, Osman et al. (11) recruited patients with hyperthy-
roidism from a university hospital, whereas euthyroid subjects
were selected either from staff members working at the hospital
or from a community center. Patients referred to university
hospitals more often exhibit (not only cardiovascular) co-
morbidities than do ambulatory-treated patients or patients re-
ferred to general hospitals. Thus, patients with overt hyperthyroid-
ism recruited for this investigation (11) are probably not
representative of hyperthyroid patients living in the study region.
Likewise, with regard to control subjects, medical staff might in
general behave healthier than the rest of the population. As a
result, excess mortality among cases compared to controls might be
explained by selection bias.
Taken together, the association between overt hyperthyroidism
and mortality found in the study of Osman et al. (11) likely results
from bias and confounding and should not necessarily be inter-
preted as a biological, causal relationship.
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